Shopping Cart
Remove All
Your shopping cart is currently empty
Grisnilimab setaritox
😃Good
Catalog No. T82259Cas No. 2361013-29-6
Alias WT1-RTA
Grisnilimab setaritox (WT1-RTA), an anti-CD7 antihuman T cell antibody linked to ricin A chain (RTA), exhibits in vitro cytotoxicity against CEM (T-lymphoblastic leukemia) cells with an ID 50 of 53 pM. The 30-kDa RTA component disrupts the function of 60S ribosomal subunits. Additionally, Grisnilimab setaritox has demonstrated efficacy in ameliorating leukemic meningitis in a rhesus monkey model [1].
Grisnilimab setaritox
Grisnilimab setaritox
😃Good
Catalog No. T82259Alias WT1-RTACas No. 2361013-29-6
Grisnilimab setaritox (WT1-RTA), an anti-CD7 antihuman T cell antibody linked to ricin A chain (RTA), exhibits in vitro cytotoxicity against CEM (T-lymphoblastic leukemia) cells with an ID 50 of 53 pM. The 30-kDa RTA component disrupts the function of 60S ribosomal subunits. Additionally, Grisnilimab setaritox has demonstrated efficacy in ameliorating leukemic meningitis in a rhesus monkey model [1].
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | Inquiry | Inquiry | |
| 5 mg | Inquiry | Inquiry | Inquiry |
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Storage & Solubility Information
| Description | Grisnilimab setaritox (WT1-RTA), an anti-CD7 antihuman T cell antibody linked to ricin A chain (RTA), exhibits in vitro cytotoxicity against CEM (T-lymphoblastic leukemia) cells with an ID 50 of 53 pM. The 30-kDa RTA component disrupts the function of 60S ribosomal subunits. Additionally, Grisnilimab setaritox has demonstrated efficacy in ameliorating leukemic meningitis in a rhesus monkey model [1]. |
| In vitro | Grisnilimab setaritox (2.5 μg/mL; 24 h) exhibits cytotoxicity against T-lymphoblastic leukemia CEM cells [1]. |
| In vivo | Grisnilimab setaritox (60 μg, 120 μg; intrathecal or intravenous injection; single dose) demonstrated potential in inhibiting T-ALL meningeal leukemia in a rhesus macaque model [1]. Additionally, grisnilimab setaritox (60 μg; intravenous injection; once weekly for six weeks, or daily for seven days) induced CSF granulocytosis and anti-immunotoxin antibodies in the same model [1]. |
| Synonyms | WT1-RTA |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | ＜ 1.0 EU/mg |
| Conjucates | Unconjugated |
| Target | CD7 |
| Cas No. | 2361013-29-6 |
| Storage | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Grisnilimab setaritox | purchase Grisnilimab setaritox | Grisnilimab setaritox cost | order Grisnilimab setaritox | Grisnilimab setaritox in vivo | Grisnilimab setaritox in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.